Table 1 Leading SARS-CoV-2 vaccine candidates supported by Operation Warp Speed in the United States
From: Development of vaccines and antivirals for combating viral pandemics
Vaccine | Technology platform | Developers | Development status and clinical trial number |
|---|---|---|---|
mRNA-1273 (ref. 29) | mRNA | Moderna Therapeutics and NIAID | Phase 3 |
BNT162b2 (ref. 30) | mRNA | BioNTech RNA Pharmaceuticals and Pfizer | Phase 3 |
AZD1222 (ref. 33) | Adenovirus vaccine | University of Oxford and AstraZeneca | Phase 3 |
Ad26.COV2-S | Adenovirus vaccine | Johnson & Johnson | Phase 3 |
– | Vesicular stomatitis virus- and measles-based | Merck Sharp and Dohme Corp. | Phase ½ |
